Neurologix, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.neurologix.net
Long Term Follow-Up Study for rAAV-GAD Treated Subjects
Terminated
- Conditions
- Parkinson's Disease
- Interventions
- Biological: rAAV-GAD
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Neurologix, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01301573
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Wake Forest University Health Science Center, Winston-Salem, North Carolina, United States
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
Phase 2
Terminated
- Conditions
- Parkinson's Disease
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Neurologix, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00643890
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Wake Forest University Health Science Center, Winston-Salem, North Carolina, United States
🇺🇸Stanford University, Stanford, California, United States
Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Neurologix, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00195143
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
© Copyright 2025. All Rights Reserved by MedPath